quizartinib (Vanflyta)

Indications

• adults with acute myeloid leukemia (AML) that carries the FLT3-ITD genetic mutation
• for use in combination with standard chemotherapy (cytarabine + anthracycline) induction followed by cytarabine consolidation & as maintenance monotherapy afterwards, in adults whose tumors express FLT3-ITD

*FDA-approved

Contraindications

• maintenance monotherapy after allogeneic hematopoietic stem cell transplantation

Mechanism of action

• targets internal tandem duplication (ITD) in mutated FLT3*

* this FLT3 mutation is associated with a higher relapse risk shorter survival

• ~1/4 of AML patients carry the mutation

* median overall survival among patients on standard chemotherapy + quizartinib is 32 months vs 15 months with standard chemotherapy + placebo

More general terms

• small inhibitory antineoplastic agent (ib drug)